en · de · es · fr · pt
selank-notes.peptides6908.com › Wiki › Selank Background And Chemical Identity — Background and Details

Selank Background And Chemical Identity — Background and Details

By Editorial Desk · published 2026-01-06 · last reviewed 2026-02-04 · Wiki

lyophilized powder is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-02-04. Where a claim depends on a specific study, the study is described rather than over-claimed.

Selank Background And Chemical Identity

The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.

Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.

Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.

Mechanism and Evidence Status

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Selank at a glance

PropertyValueNotes
Molecular classSynthetic heptapeptideStabilized analog of tuftsin
SequenceThr-Lys-Pro-Arg-Pro-Gly-ProSingle-letter form: TKPRPGP
Molecular formulaC33H57N11O9Monoisotopic mass about 751.9 Da
AppearanceWhite to off-white powderTypically supplied as lyophilized solid
SolubilityFreely soluble in waterAlso soluble in common polar solvents

Origins and Proposed Mechanisms

Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.

Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.

Related pages on this site

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Analytical Methods and Stability

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.

Background from the literature

In a solid, shear stress is a function of strain, but in a fluid, shear stress is a function of strain rate. A consequence of this behavior is Pascal's law which describes the role of pressure in characterizing a fluid's state. The behavior of fluids can be described by the Navier–Stokes equations—a set of partial differential equations which are based on:

== Plot == In 1939, Captain Daniel McCormick is a United States Army Air Corps (USAAC) test pilot. After a successful run and subsequent crash landing in a prototype North American B-25 Mitchell bomber at Alexander Field in Northern California, McCormick is greeted by his longtime friend, scientist Harry Finley, who confides that his latest experiment, "Project B", has succeeded in building a prototype chamber for cryonic freezing. The following day, just as McCormick is about to propose to his girlfriend, Helen, she goes into a coma following an automobile accident, with doctors doubting she will ever recover. Overcome with heartbreak, McCormick insists he be put into suspended animation for one year, so he will not have to watch Helen die. Fifty-three years later in 1992, ten-year-old airplane-enthusiast Nat Cooper and his friend Felix are playing inside the military storage warehouse housing the chamber, accidentally activating it and waking McCormick, leaving Nat's coat behind. McCormick awakens and escapes before realizing what year it is. He first approaches the military about his experiences, but they dismiss him as crazed; McCormick becomes more determined to learn what happened to him. McCormick follows the address on the jacket back to Nat, befriending him. While hiding in Nat's treehouse, he rescues Nat's mother Claire from her abusive ex-boyfriend Fred, slightly injuring his hand in the process.

== Remission == Remission occurs when a cat no longer requires treatment for diabetes and has normal blood glucose concentrations for at least a month. Approximately one in four cats with type 2-like diabetes achieves remission. Some studies have reported a higher remission rate than this, which may in part be due to intensive monitoring that is impractical outside of a research environment. Research studies have implicated a variety of factors in successful remission; in general, the following factors increase the likelihood of remission:

Sources: en.wikipedia.org

Further detail

== Growth == The optimal growth temperature range for B. cereus is 30–40 °C (86–104 °F). At 30 °C , a population of B. cereus can double in as little as 20 minutes or as long as 3 hours, depending on the food product. Spores of B. cereus are not metabolically active, but can rapidly become active and begin replicating once they encounter adequate growth conditions.

In April 2022, Collins embarked on her first live theatre tour, titled The GC's Big Night Out. Performing in venues across the UK, the seven-date tour was announced on 19 April 2021 and tickets went on sale on 23 April. The tour was originally scheduled to take place between 15–24 October 2021 but was postponed due to logistical issues surrounding the COVID-19 pandemic. The tour began in Manchester on 5 April 2022 and Collins was joined by Stephen Bailey who assumed the role of presenter. The show featured Collins singing, looking back at her life and career and being interviewed by Bailey before taking questions from the audience. She performed in Glasgow, Southampton, London, Birmingham and Cardiff before the tour concluded in Newcastle on 14 April. In May 2022, Collins was set to take over the role of Matron "Mama" Morton in the UK tour of the musical Chicago. Following the announcement of her casting in March, producer David Ian said "[They] were completely stunned by [Collins'] audition for the role" describing her as "an undeniable force both on and off stage" and that "audiences across the country [were] in for a treat." Collins received criticism from several actors and theatre fans on social media who described her as a "stunt casting". Responding to critics, Collins said she "auditioned for the role and trained really hard" adding that she "didn't just get it because of [her alter ego] the GC".

=== Neuropathic pain === Gabapentin is recommended as a first-line treatment for chronic neuropathic pain by various medical authorities. This is a general recommendation applicable to all neuropathic pain syndromes except for trigeminal neuralgia, where it may be used as a second- or third-line agent. Regarding the specific diagnoses, a systematic review has found evidence for gabapentin to provide pain relief for some people with postherpetic neuralgia and diabetic neuropathy. Gabapentin is approved for the former indication in the US. In addition to these two neuropathies, European Federation of Neurological Societies guideline notes gabapentin effectiveness for central pain. A combination of gabapentin with an opioid or nortriptyline may work better than either drug alone. Evidence finds little or no benefit and significant risk in those with chronic low back pain or sciatica. Gabapentin is not effective in HIV-associated sensory neuropathy and neuropathic pain due to cancer.

== External links == Clinical trial number NCT04501666 for "Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov Clinical trial number NCT04501679 for "A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov Clinical trial number NCT03985943 for "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" at ClinicalTrials.gov Clinical trial number NCT03989349 for "Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" at ClinicalTrials.gov

Sources: en.wikipedia.org

Supporting material

Coolies and POWs known as PIM (Prisonniers Internés Militaires, which is basically the same as POW) were civilians used by the army as logistical support personnel. During the battle of Dien Bien Phu, coolies were in charge of burying the corpses—during the first days only, after they were abandoned, hence giving off a terrible smell, according to veterans—and they had the dangerous job of gathering supply packets delivered in drop zones while the Việt Minh artillery was firing hard to destroy the crates. The Việt Minh also used thousands of coolies to carry the Chu-Luc (regional units) supplies and ammunition during assaults. The PIM were civilian males old enough to join Bảo Đại's army. They were captured in enemy-controlled villages, and those who refused to join the State of Vietnam's army were considered prisoners or used as coolies to support a given regiment.

=== Post-translational modifications and cofactors === Phosphorylation of the N-terminus not only prevents MDM2 binding but also facilitates the recruitment of cofactors. Pin1 enhances conformational changes in p53, while p300 and PCAF acetylate the C-terminus, exposing the DNA-binding domain and enhancing transcriptional activation. Conversely, deacetylases such as Sirt1 and Sirt7 remove these modifications, suppressing apoptosis and promoting cell survival. Some oncogenes can also activate p53 indirectly by inhibiting MDM2.

== Education == Shulman earned a Bachelor of Science degree in biophysics from the University of Michigan in 1974, graduating with high honors and distinction. He received both his M.D. and Ph.D. in physiology from Wayne State University in 1979. From 1979 to 1981, he completed his internship and residency training in internal medicine at Duke University Medical Center. He then completed his clinical and research fellowship in endocrinology and metabolism at Massachusetts General Hospital/Harvard Medical School from 1981 to 1984.

Sources: en.wikipedia.org

Frequently asked questions

What is Selank?

Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.

Where was Selank developed?

It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.

How does Selank differ from tuftsin?

Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.

What mechanisms are proposed for Selank?

Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.

Network